• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1276683 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
0 k3 y  W3 e% m6 B' R, T; \NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
, f$ P) ?6 N1 [! p+ Author Affiliations2 W5 a1 Y3 m5 f3 [

5 W( ^7 z1 c( W0 j) a+ x0 W1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
: o6 E( k( p, B5 o# T4 U; p! l2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ G' Z. F  h7 W5 |( @3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3 G$ X4 H5 {$ B: A& t4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
) x8 [( g; A2 K$ B  Q9 e* s" q5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
/ n! @. Z/ M* b7 K5 l6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
( e5 r: j# C# u! D  v% m7Kinki University School of Medicine, Osaka 589-8511, Japan
! }9 @2 a! ~% g) _8Izumi Municipal Hospital, Osaka 594-0071, Japan
0 {7 n0 h8 p: U2 N' p* _2 ~9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
3 ?( c. I9 [8 d9 a' iCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
+ G# M/ P! w8 x7 r2 K8 A+ dAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
6 s9 d7 G0 N1 Y8 {4 R' l) m, ]) d; |/ V$ E
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
& x4 i! q7 M8 `3 J% w* M4 }1 e8 l3 f  G: r- W, ~
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 8 T8 v" a+ l# ?: A# `% j: P" }/ e6 w
! I7 u0 ^2 ^! P. l- c  g
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  ! p' `+ W8 L4 T
) P/ K0 Q) s3 }' i: a' i! E0 X
Published online on: Thursday, December 1, 2011
0 A; B/ V+ K) D; j- O  H! T7 I2 K# s: K6 }0 E; Y" }! X0 S
Doi: 10.3892/ol.2011.507 % e, \& M' v' P. i# a, u5 v0 A
0 u% ]' @& h, I* k
Pages: 405-410 9 u7 {, R6 y, Q: G8 [/ I; L; B
. E; l, a7 Y% E6 l& D2 t4 \& h
Abstract:
7 t* i9 c$ ^) Y& F& q% q( G- @, [S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
, c7 K2 X3 Z$ T2 p/ ] " c( v  L' |: O1 A3 j8 v
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population  S5 j% k$ k5 K( ?( V
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
" o+ F+ V9 D$ B8 |  T- G8 X+ Author Affiliations
# @4 D# o6 v+ H5 l1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
7 F# M+ e1 P4 m/ I; c* P: s2Department of Thoracic Surgery, Kyoto University, Kyoto ! g) \0 ?" o$ {! C1 G  W
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan - n$ N8 c% m" Q5 {5 j( o6 a
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp % a1 k& o( n2 A. O4 O5 b
Received September 3, 2010. 8 u; Y. m  J( ?; k: i
Revision received November 11, 2010.
2 ]: T0 d/ ^& Y6 ^- v! C' OAccepted November 17, 2010. / `- p2 |$ F5 a9 K
Abstract
  @/ e9 T, {, s( PBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
7 ]  J9 ]' A9 |, r& S/ r9 ]3 {Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. . ?3 K: N, [3 q( A8 j  G2 f# a
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. $ ^5 q" J# `: Z) u
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 4 K. S6 U7 G4 z' W
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。& |; L/ d; r4 ^/ N: {% F& a: \$ h! J
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?$ B* j7 n0 ?& d" T5 Y6 u6 C+ }
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
/ Y) C" M7 Y1 ~0 Y$ `( Lhttp://clinicaltrials.gov/ct2/show/NCT01523587
% D8 U1 g3 G7 L1 `$ O( K- A  r* B! [3 U+ a
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC$ \1 R5 Y+ g" @% e  N/ p! o& \
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
# h- n9 _) s* d1 D: _" {  U* t- I& x) H7 E
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。7 W$ A  U  V5 O; q
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 9 {# ]1 I3 |2 S: i* W
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
  c9 D7 l- [0 [" Y. S至今为止,未出 ...
/ H/ |7 D# @3 n
没有副作用是第一追求,效果显著是第二追求。
* T/ {. w1 G* m& z1 I/ E. r不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表